SCHEMBL10126006

SCHEMBL10126006

Cc1cc(-c2nc3ccccc3o2)c(C)cc1-c1ccc(-c2nc3ccccc3nc2-c2ccc(-c3cc(C)c(-c4nc5ccccc5o4)cc3C)cc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.52
ALDH1A1 P00352 7/20 0.52
HPGD P15428 6/20 0.52
MAPT P10636 5/20 0.52
USP2 O75604 2/20 0.52
TDP1 Q9NUW8 2/20 0.52
PTGS2 P35354 3/20 0.51
NPC1 O15118 10/20 0.50
RAB9A P51151 8/20 0.50
SMN1; SMN2 Q16637 6/20 0.50
HSD17B10 Q99714 5/20 0.50
HCRTR1 O43613 2/20 0.50
TSHR P16473 2/20 0.50
CASP3 P42574 2/20 0.50
SENP8 Q96LD8 2/20 0.50
SENP7 Q9BQF6 2/20 0.50
SENP6 Q9GZR1 2/20 0.50
MAPK1 P28482 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
NFKB1 P19838 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10125821 0.97 KDM4E (0.53) KDM4EALDH1A1HPGDMAPTUSP2
SCHEMBL10125840 0.89 NPC1 (0.51) KDM4EALDH1A1HPGDMAPTUSP2
SCHEMBL10126020 0.89 NPC1 (0.55) KDM4EALDH1A1HPGDMAPTUSP2
SCHEMBL10126005 0.85 PTGS2 (0.63) KDM4EALDH1A1HPGDMAPTUSP2
SCHEMBL10315449 0.83 KDM4E (0.45) KDM4EALDH1A1HPGDMAPTUSP2
SCHEMBL10126009 0.82 ALDH1A1 (0.51) KDM4EALDH1A1HPGDMAPTUSP2
SCHEMBL10125824 0.82 PTGS2 (0.60) KDM4EALDH1A1HPGDMAPTUSP2
SCHEMBL10315240 0.82 KDM4E (0.44) KDM4EALDH1A1HPGDMAPTUSP2
SCHEMBL834208 0.81 NPC1 (0.52) KDM4EALDH1A1HPGDMAPTUSP2
SCHEMBL10126011 0.81 PTGS2 (0.52) KDM4EALDH1A1HPGDMAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119259-B2 Quinoxaline derivative, and light-emitting element and electronic device using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-21 US disclosed
US-8119259-B2 Quinoxaline derivative, and light-emitting element and electronic device using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-21 US disclosed
US-20090140642-A1 Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-06-04 US disclosed
US-20090140642-A1 Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090140642-A1 Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same NDUFA11, NDUFA9, NDUFA12 KDM4E 2216/4885ALDH1A1 345/4885HPGD 463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.